Epidemiology of inclusion body myositis in the Netherlands: A nationwide study

Article abstract Epidemiologic data on inclusion body myositis (IBM) are scarce, and possibly biased, because they are derived from larger neuromuscular centers. The present nationwide collaborative cross-sectional study, which culminated on July 1, 1999, resulted in identification of 76 patients with IBM and the establishment of a prevalence of 4.9 patients with IBM per million inhabitants in the Netherlands. Several discrepancies suggest that this may be an underestimation. The most frequently identified pitfall in diagnosing IBM was an erroneous diagnosis of polymyositis or motor neuron disease.

[1]  W. Engel,et al.  βAPP gene transfer into cultured human muscle induces inclusion‐body myositis aspects , 1997 .

[2]  W J Litchy,et al.  Inclusion body myositis. Observations in 40 patients. , 1989, Brain : a journal of neurology.

[3]  B. Katirji.  Diagnostic Criteria for Neuromuscular Disorders , 1994, Neurology.

[4]  A. Oldfors,et al.  Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases , 1994, Acta Neurologica Scandinavica.

[5]  R. Gherardi,et al.  Inclusion body myositis in French patients. A clinicopathological evaluation , 1990, Neuropathology and applied neurobiology.

[6]  Richard J. Barohn,et al.  Inclusion body myositis , 2000, Current treatment options in neurology.

[7]  M. Dalakas,et al.  Inclusion body myositis and myopathies , 1997, Journal of the Neurological Sciences.

[8]  L. Calabrese,et al.  Inclusion body myositis: analysis of 32 cases. , 1992, The Journal of rheumatology.

[9]  R. Powell,et al.  Inclusion body myositis: an underdiagnosed condition? , 1993, Annals of the rheumatic diseases.